Novo, Nordisk

Novo Nordisk Gears Up for Swedish Wegovy Launch as Parallel Imports Steal a March

Published on 11/22/2026 at 13:01 | Editorial boerse-global.de
Swedish pharmacies stock Novo Nordisk's Wegovy pill through parallel imports, but official launch date and price remain undisclosed as reimbursement stays open.
Novo, Nordisk, Gears, Swedish, Wegovy, Launch, Parallel, Imports, Steal, March Illustration mit AI erstellt.

Swedish pharmacies have begun stocking Novo Nordisk's Wegovy pill through parallel imports, local media report, even though the Danish drugmaker has yet to fire the starting gun on its own official rollout in the country. The development gives the obesity treatment a head start on pharmacy shelves while leaving two central questions — launch date and price — unanswered.

Novo Sverige intends to disclose both the price and the introduction date together. According to Swedish press reports, the price is expected to land in the same territory as comparable GLP-1 injections, which can run to several thousand kronor a month. Parallel imports therefore pre-empt part of the official launch without shedding any light on the price Novo Nordisk itself will set.

Reimbursement is the second open front. Sweden's TLV authority has turned down subsidisation of Wegovy on repeated occasions, and Novo Nordisk filed a fresh application in the autumn. Spain illustrates how much weight the reimbursement question carries: oral semaglutide has been available in Spanish pharmacies since 1 November, yet La Vanguardia reports that the public health system covers neither the pill nor the injection.

A Revenue Contributor Already

The pill's commercial weight is already visible in the numbers. Following the US launch in January, oral Wegovy generated revenue of DKK 5.39 billion in the third quarter of 2026. That performance coincides with an upgraded group forecast — Novo Nordisk has raised its 2026 outlook for both sales and operating profit for the third time, now guiding to a range spanning a 2% decline to 2% growth on both measures.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

By mid-2027, the company aims to bring the tablet to more than 20 countries, a plan that hinges on manufacturing capacity and regulatory approvals. For Sweden specifically, two concrete decisions lie ahead: when Novo opens official distribution and at what price it offers the pill.

Pipeline Momentum Across the Portfolio

The Swedish rollout sits alongside a dense stretch of clinical and corporate news. Novo Nordisk and nference announced on 18 November a collaboration to research cardiovascular and metabolic disease as well as healthy ageing, linking Novo's clinical trial data with nference's AI platform and health data network. Shares of Novo Nordisk fell 3.0% on Friday.

On the paediatric front, Novo Nordisk reported on 16 November results from the Phase 3 STEP Young trial of Wegovy in children with obesity aged six to under twelve. Nearly 80% of children treated with Wegovy saw their body-mass index drop by at least 10%, while no child in the placebo arm reached that threshold.

Denmark's patient compensation body awarded payouts on 17 November to a total of 31 patients amounting to DKK 15 million, in cases involving suspected NAION eye disease following treatment with Wegovy or Ozempic.

Lower-dose CagriSema also delivered data on 14 November, with Phase 3 REDEFINE 9 results estimating average weight loss of 20.7% and 21.0% for the two dose levels. The estimates cover 68 weeks and assume all patients had continued treatment.

Ad

Novo Nordisk Stock: New Analysis - 22 November

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

Disclaimer...
en | DK0062498333 | NOVO | boerse | 70544259 |